Abirtega Tablet
Product Images NDC 82249-011

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Abirtega (NDC 82249-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abiraterone-acetate-tablets-1.jpg (Abiraterone Acetate Tablets 1)

Chemical structure of abiraterone acetate, the active ingredient in Abirtega 250 mg oral tablets, illustrating its molecular framework with steroidal rings and attached functional groups including an acetate moiety and a pyridine ring.*

FDA Label Image

Abirtega-tablets-250mg-120s-2laabi250tca-e-10-2024.jpg (Abirtega Tablets 250mg 120s 2laabi250tca E 10 2024)

Label for Abirtega (abiraterone acetate) tablets, USP, 250 mg oral tablets. The label includes dosage and storage instructions, warnings for women who are or may be pregnant, and handling precautions. It also provides manufacturer and distributor information, a QR code, and a barcode. The product is distributed by CivicaScript, LLC.*

FDA Label Image

Civicascript-corporate-logo.jpg (Civicascript Corporate Logo 01)

FDA Label Image

Civicascript-corporate-logo.jpg (Civicascript Corporate Logo)

FDA Label Image

Figure-1 (Image 01)

A Kaplan-Meier survival curve chart comparing percentage survival over time in months for Abiraterone acetate versus placebo. The chart shows survival percentages on the Y-axis and time to death in months on the X-axis. The graph includes lines representing Abiraterone acetate and placebo, with a table below indicating numbers at risk at various time points.*

FDA Label Image

Figure-2 (Image 02)

A Kaplan-Meier survival curve chart showing the percentage of subjects without death over months from randomization, comparing Abiraterone Acetate and Placebo groups. The chart includes two lines: a solid line for Abiraterone Acetate and a dashed line for Placebo, with subject counts at risk below the x-axis.*

FDA Label Image

Figure-3 (Image 03)

A Kaplan-Meier survival curve depicting the percentage of subjects without radiographic progression or death over months from randomization. Two groups are compared: Abiraterone Acetate (solid line) and Placebo (dashed line), with the number of subjects at risk shown below the x-axis over time.*

FDA Label Image

Figure-4 (Image 04)

A Kaplan-Meier survival curve graph showing the percentage of subjects without death over time in months from randomization. It compares survival between two groups: Abiraterone acetate and Placebo. The graph includes data on the number of subjects at risk at different time points for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.